---
document_datetime: 2025-12-02 05:11:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/colobreathe.html
document_name: colobreathe.html
version: success
processing_time: 0.1492676
conversion_datetime: 2025-12-28 14:27:41.690783
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Colobreathe

[RSS](/en/individual-human-medicine.xml/66719)

##### Authorised

This medicine is authorised for use in the European Union

colistimethate sodium Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Colobreathe](#more-information-on-colobreathe-768)
- [More information on Colobreathe](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Colobreathe. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Colobreathe.

Expand section

Collapse section

## What is Colobreathe?

Colobreathe is a medicine that contains the active substance colistimethate sodium. It is available as capsules containing a powder for inhalation using an inhaler device.

## What is Colobreathe used for?

Colobreathe is used to manage long-term lung infection caused by the bacteria *Pseudomonas aeruginosa* in patients aged six years and over who have cystic fibrosis.

Cystic fibrosis is an inherited disease that affects the cells in the lungs and the glands in the gut and pancreas which secrete fluids such as mucus and digestive juices. In cystic fibrosis, these fluids become thick and viscous, blocking the airways and the flow of digestive juices. The accumulation of mucus in the lungs allows bacteria to grow more easily causing infections, lung damage and breathing problems. Bacterial lung infection with *P. aeruginosa* is frequent in cystic-fibrosis patients.

The medicine can only be obtained with a prescription.

## How is Colobreathe used?

The contents of Colobreathe capsules are inhaled using a powder inhaler called Turbospin. They are not to be inhaled using any other device.

The recommended dose is one capsule twice daily, taken as close as possible to 12 hours apart. The very first dose at the start of the treatment should be taken under medical supervision. Treatment may continue for as long as the doctor considers that the patient is benefiting from it.

If the patient is also receiving other treatments for cystic fibrosis, they should be taken in the following order: inhaled bronchodilator, chest physiotherapy, other inhaled medicines and then Colobreathe.

## How does Colobreathe work?

The active substance in Colobreathe, colistimethate sodium, is an antibiotic in the polymyxin group. Polymyxins work by disrupting the cell membrane of bacteria by interacting with certain components of the membrane called phospholipids. Polymyxins target a group of bacteria called Gram-negative bacteria, which includes *P. aeruginosa* , because their cell membranes contain a high level of phospholipids.

Colistimethate sodium is a well known antibiotic that has been used for several years to treat lung infection in cystic-fibrosis patients and is available in the form of a solution used with a nebuliser (a machine that changes a solution into an aerosol that the patient can breathe in). Colobreathe, as a powder for inhalation, is expected to be more convenient for patients than nebulisers.

## How has Colobreathe been studied?

The effects of Colobreathe were first tested in experimental models before being studied in humans.

Colobreathe was compared with another medicine, tobramycin nebuliser solution, in 380 cystic-fibrosis patients aged six years and above with *P. aeruginosa* lung infection. The patients' condition had been stabilised by treatment with tobramycin before the study. The main measure of effectiveness was based on the improvement in FEV1, adjusted for the patients' age and height, after 24 weeks. FEV1 is the most air a person can breathe out in one second.

## What benefit has Colobreathe shown during the studies?

Colobreathe compared well with the tobramycin treatment, considering the fact that the patients were already stabilised on tobramycin nebuliser. Among patients that completed the study, the improvement in FEV1 adjusted for age and height was 0.39% with Colobreathe compared with 0.78% with tobramycin. The improvements in FEV1 seen with Colobreathe were considered sufficient proof of effectiveness, considering the fact that the patients in the study were already stabilised on tobramycin nebuliser.

## What is the risk associated with Colobreathe?

The most common side effects seen with Colobreathe in studies were: unpleasant taste, cough, throat irritation, difficulty breathing and dysphonia (difficulty speaking). Inhalation may also lead to coughing or bronchospasm (tightening of the muscles in the airway), which may be controlled by first treating the patients with inhaled beta-2-agonist medicines. For the full list of all side effects reported with Colobreathe, see the package leaflet.

Colobreathe must not be used in people who are hypersensitive (allergic) to colistimethate sodium or to colistin sulphate or polymyxin B.

## Why has Colobreathe been approved?

The CHMP concluded that the modest improvement in FEV1 seen with Colobreathe was sufficient evidence of the medicine's effectiveness, given that larger improvements would not be expected in patients whose condition was already stabilised on tobramycin nebuliser. In addition, the Committee noted that patients generally prefer inhaling powder to using a nebuliser.

The side effects seen with Colobreathe were considered acceptable. No more serious side effects were seen with Colobreathe than with tobramycin.

The Committee therefore decided that the benefits of Colobreathe are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe use of Colobreathe?

The company that makes Colobreathe will supply education packs to patients and healthcare professionals. The packs will contain information on the need to comply with treatment, instructions on how to use the medicine and information on side effects.

## Other information about Colobreathe

The European Commission granted a marketing authorisation valid throughout the European Union for Colobreathe on 13 February 2012.

For more information about treatment with Colobreathe, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Colobreathe : EPAR - Summary for the public

Reference Number: EMA/135145/2012

English (EN) (71.3 KB - PDF)

**First published:** 07/03/2012

**Last updated:** 07/03/2012

[View](/en/documents/overview/colobreathe-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-355)

български (BG) (111.92 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/bg/documents/overview/colobreathe-epar-summary-public_bg.pdf)

español (ES) (79.79 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/es/documents/overview/colobreathe-epar-summary-public_es.pdf)

čeština (CS) (89.63 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/cs/documents/overview/colobreathe-epar-summary-public_cs.pdf)

dansk (DA) (60.15 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/da/documents/overview/colobreathe-epar-summary-public_da.pdf)

Deutsch (DE) (77.58 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/de/documents/overview/colobreathe-epar-summary-public_de.pdf)

eesti keel (ET) (60.23 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/et/documents/overview/colobreathe-epar-summary-public_et.pdf)

ελληνικά (EL) (103.8 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/el/documents/overview/colobreathe-epar-summary-public_el.pdf)

français (FR) (60.16 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/fr/documents/overview/colobreathe-epar-summary-public_fr.pdf)

italiano (IT) (62.71 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/it/documents/overview/colobreathe-epar-summary-public_it.pdf)

latviešu valoda (LV) (88.94 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/lv/documents/overview/colobreathe-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (89.23 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/lt/documents/overview/colobreathe-epar-summary-public_lt.pdf)

magyar (HU) (84.14 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/hu/documents/overview/colobreathe-epar-summary-public_hu.pdf)

Malti (MT) (87.78 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/mt/documents/overview/colobreathe-epar-summary-public_mt.pdf)

Nederlands (NL) (75.75 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/nl/documents/overview/colobreathe-epar-summary-public_nl.pdf)

polski (PL) (88.99 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/pl/documents/overview/colobreathe-epar-summary-public_pl.pdf)

português (PT) (59.82 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/pt/documents/overview/colobreathe-epar-summary-public_pt.pdf)

română (RO) (86.87 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/ro/documents/overview/colobreathe-epar-summary-public_ro.pdf)

slovenčina (SK) (86.22 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/sk/documents/overview/colobreathe-epar-summary-public_sk.pdf)

slovenščina (SL) (83.74 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/sl/documents/overview/colobreathe-epar-summary-public_sl.pdf)

Suomi (FI) (74.98 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/fi/documents/overview/colobreathe-epar-summary-public_fi.pdf)

svenska (SV) (60.25 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/sv/documents/overview/colobreathe-epar-summary-public_sv.pdf)

Colobreathe : EPAR - Risk management plan

English (EN) (3.8 MB - PDF)

**First published:** 18/03/2020

**Last updated:** 30/09/2024

[View](/en/documents/rmp-summary/colobreathe-epar-risk-management-plan_en.pdf)

## Product information

Colobreathe : EPAR - Product Information

English (EN) (434.83 KB - PDF)

**First published:** 07/03/2012

**Last updated:** 20/06/2025

[View](/en/documents/product-information/colobreathe-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-342)

български (BG) (547.79 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/bg/documents/product-information/colobreathe-epar-product-information_bg.pdf)

español (ES) (446.32 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/es/documents/product-information/colobreathe-epar-product-information_es.pdf)

čeština (CS) (511.28 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/cs/documents/product-information/colobreathe-epar-product-information_cs.pdf)

dansk (DA) (444.47 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/da/documents/product-information/colobreathe-epar-product-information_da.pdf)

Deutsch (DE) (449.85 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/de/documents/product-information/colobreathe-epar-product-information_de.pdf)

eesti keel (ET) (438.25 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/et/documents/product-information/colobreathe-epar-product-information_et.pdf)

ελληνικά (EL) (538.8 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/el/documents/product-information/colobreathe-epar-product-information_el.pdf)

français (FR) (487.47 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/fr/documents/product-information/colobreathe-epar-product-information_fr.pdf)

hrvatski (HR) (631.27 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/hr/documents/product-information/colobreathe-epar-product-information_hr.pdf)

íslenska (IS) (453.07 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/is/documents/product-information/colobreathe-epar-product-information_is.pdf)

italiano (IT) (469.07 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/it/documents/product-information/colobreathe-epar-product-information_it.pdf)

latviešu valoda (LV) (551.76 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/lv/documents/product-information/colobreathe-epar-product-information_lv.pdf)

lietuvių kalba (LT) (526.82 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/lt/documents/product-information/colobreathe-epar-product-information_lt.pdf)

magyar (HU) (573.86 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/hu/documents/product-information/colobreathe-epar-product-information_hu.pdf)

Malti (MT) (526.29 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/mt/documents/product-information/colobreathe-epar-product-information_mt.pdf)

Nederlands (NL) (467.96 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/nl/documents/product-information/colobreathe-epar-product-information_nl.pdf)

norsk (NO) (449.98 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/no/documents/product-information/colobreathe-epar-product-information_no.pdf)

polski (PL) (540.8 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/pl/documents/product-information/colobreathe-epar-product-information_pl.pdf)

português (PT) (468.31 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/pt/documents/product-information/colobreathe-epar-product-information_pt.pdf)

română (RO) (544.62 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/ro/documents/product-information/colobreathe-epar-product-information_ro.pdf)

slovenčina (SK) (522.13 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/sk/documents/product-information/colobreathe-epar-product-information_sk.pdf)

slovenščina (SL) (535.51 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/sl/documents/product-information/colobreathe-epar-product-information_sl.pdf)

Suomi (FI) (437.88 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/fi/documents/product-information/colobreathe-epar-product-information_fi.pdf)

svenska (SV) (437.67 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

20/06/2025

[View](/sv/documents/product-information/colobreathe-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0063 18/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Colobreathe : EPAR - All Authorised presentations

English (EN) (45.21 KB - PDF)

**First published:** 07/03/2012

**Last updated:** 27/09/2013

[View](/en/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-27)

български (BG) (77.18 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/bg/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.84 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/es/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.6 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/cs/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.11 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/da/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.1 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/de/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.56 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/et/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.74 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/el/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_el.pdf)

français (FR) (59.5 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/fr/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (74.3 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/hr/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (57.25 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/is/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.28 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/it/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (75.81 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/lv/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (76.38 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/lt/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (61.18 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/hu/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.6 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/mt/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.14 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/nl/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (55.47 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/no/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_no.pdf)

polski (PL) (75.93 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/pl/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.37 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/pt/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_pt.pdf)

română (RO) (73.23 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/ro/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (78.04 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/sk/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (74.34 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/sl/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.62 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/fi/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.59 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

27/09/2013

[View](/sv/documents/all-authorised-presentations/colobreathe-epar-all-authorised-presentations_sv.pdf)

Colobreathe : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (104.37 KB - PDF)

**First published:** 07/03/2012

**Last updated:** 07/03/2012

[View](/en/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (22)](#file-language-dropdown-201)

български (BG) (150.75 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/bg/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (33.25 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/es/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (102.95 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/cs/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (97.16 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/da/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (107.93 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/de/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (33.07 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/et/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (103.83 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/el/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (155.32 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/fr/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

hrvatski (HR) (109.91 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/hr/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_hr.pdf)

italiano (IT) (32.57 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/it/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (154.92 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/lv/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (101.99 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/lt/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (97.6 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/hu/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (163.22 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/mt/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (116.9 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/nl/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

polski (PL) (149.03 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/pl/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (106.48 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/pt/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (155.89 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/ro/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (101.39 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/sk/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (151.32 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/sl/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (43.51 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/fi/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (94.46 KB - PDF)

**First published:**

07/03/2012

**Last updated:**

07/03/2012

[View](/sv/documents/conditions-member-states/colobreathe-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Colobreathe Active substance Colistimethate sodium International non-proprietary name (INN) or common name colistimethate sodium Therapeutic area (MeSH) Cystic Fibrosis Anatomical therapeutic chemical (ATC) code J01XB01

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Colobreathe is indicated for the management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in patients with cystic fibrosis (CF) aged six years and older.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/001225 Marketing authorisation holder

Essential Pharma Limited

Vision Exchange Building Triq it-Territorjals, Zone 1 Central Business District Birkirkara CBD 1070 Malta

Marketing authorisation issued 13/02/2012 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Colobreathe : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (238.07 KB - PDF)

**First published:** 10/09/2012

**Last updated:** 20/06/2025

[View](/en/documents/procedural-steps-after/colobreathe-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Colobreathe-H-C-1225-A31-0007 : EPAR - Scientific conclusions and grounds for maintenance of the marketing authorisations or the variation to the terms of the marketing authorisations

English (EN) (56.5 KB - PDF)

**First published:** 06/07/2015

**Last updated:** 06/07/2015

[View](/en/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_en.pdf)

[Other languages (22)](#file-language-dropdown-70)

български (BG) (93.19 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/bg/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_bg.pdf)

español (ES) (57.82 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/es/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_es.pdf)

čeština (CS) (92.94 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/cs/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_cs.pdf)

dansk (DA) (56.19 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/da/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_da.pdf)

Deutsch (DE) (60.15 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/de/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_de.pdf)

eesti keel (ET) (56.74 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/et/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_et.pdf)

ελληνικά (EL) (96.55 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/el/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_el.pdf)

français (FR) (58.55 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/fr/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_fr.pdf)

hrvatski (HR) (88.56 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/hr/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_hr.pdf)

italiano (IT) (81.31 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/it/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_it.pdf)

latviešu valoda (LV) (90.79 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/lv/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_lv.pdf)

lietuvių kalba (LT) (89.7 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/lt/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_lt.pdf)

magyar (HU) (89.45 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/hu/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_hu.pdf)

Malti (MT) (94.38 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/mt/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_mt.pdf)

Nederlands (NL) (59.91 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/nl/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_nl.pdf)

polski (PL) (90.38 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/pl/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_pl.pdf)

português (PT) (58.39 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/pt/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_pt.pdf)

română (RO) (129.95 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/ro/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_ro.pdf)

slovenčina (SK) (79.74 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/sk/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_sk.pdf)

slovenščina (SL) (86.41 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/sl/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_sl.pdf)

Suomi (FI) (56.71 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/fi/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_fi.pdf)

svenska (SV) (57.42 KB - PDF)

**First published:**

06/07/2015

**Last updated:**

06/07/2015

[View](/sv/documents/scientific-conclusion/colobreathe-h-c-1225-a31-0007-epar-scientific-conclusions-and-grounds-maintenance-marketing-authorisations-or-variation-terms-marketing-authorisations_sv.pdf)

Colobreathe-H-C-1225-A31-0007: EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/707128/2014

English (EN) (259.83 KB - PDF)

**First published:** 05/01/2015

**Last updated:** 05/01/2015

[View](/en/documents/variation-report/colobreathe-h-c-1225-a31-0007-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Colobreathe : EPAR - Public assessment report

Adopted

Reference Number: EMA/913717/2011

English (EN) (812.23 KB - PDF)

**First published:** 07/03/2012

**Last updated:** 07/03/2012

[View](/en/documents/assessment-report/colobreathe-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Colobreathe

Adopted

Reference Number: EMA/CHMP/754272/2011

English (EN) (46.53 KB - PDF)

**First published:** 29/09/2011

**Last updated:** 29/09/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-colobreathe_en.pdf)

#### More information on Colobreathe

- [Article 31 Referral: Polymyxin-containing medicines](/en/medicines/human/referrals/polymyxin-containing-medicines)

Assessment report for Article-5(3) procedure: Polymyxin-based products

Adopted

Reference Number: EMA/CHMP/153652/2015

Summary:

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

English (EN) (227.93 KB - PDF)

**First published:** 26/05/2015

**Last updated:** 26/05/2015

[View](/en/documents/referral/assessment-report-article-53-procedure-polymyxin-based-products_en.pdf)

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu302088) on 19 February 2002. Colobreathe was withdrawn from the Community register of orphan medicinal products in December 2012 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Colobreathe

- [Polymyxin-containing medicines - referral](/en/medicines/human/referrals/polymyxin-containing-medicines)
- [EMEA-000176-PIP01-07-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000176-pip01-07-m05)
- [A Cross-sectional Study to Evaluate the Effectiveness of the Colobreathe Risk Minimisation Educational Programme Among Healthcare Professionals and Patients - post-authorisation study](https://catalogues.ema.europa.eu/study/34147)
- [An Open-label Observational Safety Study of Colobreathe® (colistimethate sodium dry powder for inhalation) Compared with Other Inhaled Anti-pseudomonal Antibiotics in Cystic Fibrosis Patients Using Cystic Fibrosis Registries - post-authorisation study](https://catalogues.ema.europa.eu/study/34038)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/06/2025

## Share this page

[Back to top](#main-content)